Adenosine
- Generic Name
- Adenosine
- Brand Names
- Adenocard, Viva-drops Lubricating Eye Drops
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 58-61-7
- Unique Ingredient Identifier
- K72T3FS567
- Background
The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia.
Adenosine was granted FDA approval on 30 October 1989.
- Indication
Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.
- Associated Conditions
- Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)
Dose-Response of Adenosine for Perioperative Pain
- Conditions
- Perioperative Pain
- First Posted Date
- 2006-03-02
- Last Posted Date
- 2006-08-02
- Lead Sponsor
- Xsira Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT00298636
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸University of Miami/Miller School of Medicine, Miami, Florida, United States
🇺🇸Medical College of Georgia, Augusta, Georgia, United States
Salvage: Postconditioning With Adenosine for STEMI
- Conditions
- Acute ST Elevation Myocardial Infarction
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2006-01-31
- Lead Sponsor
- University Hospital, Gasthuisberg
- Target Recruit Count
- 100
- Registration Number
- NCT00284323
- Locations
- 🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia
- Conditions
- Blood Flow in Healthy Volunteers
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2007-04-05
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT00253929
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1231
- Registration Number
- NCT00208299
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 787
- Registration Number
- NCT00208312
- Locations
- 🇺🇸
Multiple study locations (see Central Contact); CV Therapeutics, Inc., Palo Alto, California, United States
Ischemic Injury and Ischemic Preconditioning in Diabetes
- Conditions
- Diabetes Mellitus, Insulin-DependentIschemia-Reperfusion Injury
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-04-05
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00184821
- Locations
- 🇳🇱
Clinical Research Centre Nijmegen; Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Adenosine Receptors Influence Ischemia-Reperfusion Injury
- Conditions
- Ischemia-Reperfusion Injury
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT00184847
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre/Department of Pharmacology and Toxicology, Nijmegen, Gelderland, Netherlands
AMP as a Better Delivery System of Adenosine
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00179010
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.